GE Healthcare Inks Biosimilar Engineering Pact with M+W Group

The deal will combine GE Healthcare’s expertise in technologies for biopharmaceutical manufacture with M+W Group’s global capabilities in bio-engineering and construction to assist countries to become self-sufficient in the manufacture of biologics.

GE Healthcare and M+W Group have formed a strategic alliance that will combine GE Healthcare’s expertise in technologies for biopharmaceutical manufacture with M+W Group’s global capabilities in bio-engineering and construction to assist countries to become self-sufficient in the manufacture of biologics such as vaccines, insulin and biosimilars.

The companies "will offer governments and pharmaceutical companies an integrated, cost-competitive turnkey approach for the construction of biopharmaceutical manufacturing plants, to help meet the rapidly increasing worldwide demand for these potentially life-saving treatments," according to a joint statement.

Olivier Loeillot, general manager of Enterprise Solutions, GE Healthcare Life Sciences, said, “By working together to bring a